Strata Critical Medical stock
SRTANASDAQStrata Critical Medical, Inc., HealthcareISIN US0926671043
47Score 47 out of 100, Weak
Price and trend
70 / 100
Price history
+19% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 18% above it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 76).
The price is 7.1% below its 52-week high. Largest decline in 7 years: 89% (February 2021 to November 2023).
Chart figures for advanced users
- SMA 50$5.01
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.09
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)76
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.03
- The lowest closing price of the last twelve months.
- Resistance$6.47
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Strata Critical Medical, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $536.81M, is number 49 of 56 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $289.86M (up 47%) and adjusted earnings per share of −$0.11.
- MEQIRI Score 47 out of 100 (Weak): rank 437 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 60.3% a year since 2019, Medical (Care Facilities) median 9.2%.Growth 70
- More cash than debtCash $41.64M, financial debt $3.62M.Stability 72
Weaknesses
- Loss-makingLoss of $24.81M over the last 12 months.Fundamentals 17
- DilutionShare count up 18% since 2021.Capital allocation 20
- Volatile share priceVolatility 57% a year over the last 12 months.
Its standout strengths are momentum and stability, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 50.3% on the same quarter a year earlier. Up to 2024 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 60.3% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 21%, operating −11%, net not measured.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 2 Mar 2027in 110 days
- Last reported
- 3 Nov 2026EPS reported −$0.05 (expected −$0.01)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 18.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.11−18.9%
- Revenue
- $289.86M−0.3%
- Earnings per share
- $0.09+2,450.3%
- Revenue
- $324M−0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +5.4%2026 revenue guidance raised to $285 million to $295 million (previously $260 million to $275 million) and adjusted EBITDA to $33 million to $35 million (previously $29 million to $33 million).
“We are also increasing our 2026 adjusted EBITDA guidance to a range of $33 million to $35 million, up from $29 million to $33 million previously.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $9,998 in total. 5 insiders sold, $749,036 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Lauck AndrewPurchase
5 Nov 2026, Board
- Shares
- 2,000
- Price
- $5.00
- Value
- $9,998
- Love ReginaldSale
10 Aug 2026, Board
- Shares
- 5,091
- Price
- $5.75
- Value
- $29,273
- Heyburn William A.Sale
8 Jun 2026, Co-CEO and CFO
- Shares
- 31,671
- Price
- $5.87
- Value
- $185,909
Show 5 more
- Cohen AmirSale
8 Jun 2026, Chief Accounting Officer
- Shares
- 4,655
- Price
- $5.87
- Value
- $27,325
- Tomkiel Melissa M.Sale
8 Jun 2026, Co-CEO and General Counsel
- Shares
- 29,730
- Price
- $5.87
- Value
- $174,515
- Wunsch Scott MSale
8 Jun 2026, CEO, Logistics
- Shares
- 5,550
- Price
- $5.87
- Value
- $32,579
- Cohen AmirSale
22 May 2026, Chief Accounting Officer
- Shares
- 40,575
- Price
- $5.91
- Value
- $239,798
- Cohen AmirSale
21 May 2026, Chief Accounting Officer
- Shares
- 10,300
- Price
- $5.79
- Value
- $59,637
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Strata Critical Medical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Ramsay Générale de SantéGDS.PA $1.07B39
- Clínica BavieraCBAV.MC $938.33M80
- TerveystaloTTALO.HE $873.42M51
- GMR SolutionsGMRS $635.3M57
- Starling OncologySTLN $419.93M26
- M1 KlinikenM12.DE $402.19M74
- AunaAUNA $347.12M43
- Viemed HealthcareVMD $345.96M65
ETFs that hold Strata Critical Medical
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 23 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.